Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

A 66-year-old male experienced significant hair regrowth using topical finasteride for 5 years and oral minoxidil for 3.5 years, with no side effects. He is now switching from finasteride to topical dutasteride 0.1% to potentially improve results further.

A 66-year-old male experienced significant hair regrowth using topical finasteride for 5 years and oral minoxidil for 3.5 years, with no side effects. He is now switching from finasteride to topical dutasteride while continuing oral minoxidil to potentially improve results further.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

Androsterone may help with sexual and affective dysfunction from finasteride by replacing disrupted neurosteroids without increasing androgenic side effects. Controlled testing is needed to confirm its effectiveness and safety.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.